Cyclopharm Ltd (CYC) - Total Assets
Based on the latest financial reports, Cyclopharm Ltd (CYC) holds total assets worth AU$46.10 Million AUD (≈ $32.62 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Cyclopharm Ltd (CYC) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cyclopharm Ltd - Total Assets Trend (2005–2025)
This chart illustrates how Cyclopharm Ltd's total assets have evolved over time, based on quarterly financial data. Check Cyclopharm Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Cyclopharm Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Cyclopharm Ltd's total assets of AU$46.10 Million consist of 61.7% current assets and 38.3% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 14.4% |
| Accounts Receivable | AU$8.59 Million | 18.6% |
| Inventory | AU$11.43 Million | 24.8% |
| Property, Plant & Equipment | AU$13.40 Million | 29.1% |
| Intangible Assets | AU$1.70 Million | 3.7% |
| Goodwill | AU$974.61K | 2.1% |
Asset Composition Trend (2005–2025)
This chart illustrates how Cyclopharm Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Cyclopharm Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cyclopharm Ltd's current assets represent 61.7% of total assets in 2025, an increase from 61.2% in 2005.
- Cash Position: Cash and equivalents constituted 14.4% of total assets in 2025, down from 41.2% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 31.0% in 2005.
- Asset Diversification: The largest asset category is property, plant & equipment at 29.1% of total assets.
Cyclopharm Ltd Competitors by Total Assets
Key competitors of Cyclopharm Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Excelsior Medical Co Ltd
TW:4104
|
Taiwan | NT$18.80 Billion |
|
Sigma Healthcare Ltd
AU:SIG
|
Australia | AU$8.74 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$8.80 Billion |
|
Paragon Care Ltd
AU:PGC
|
Australia | AU$1.31 Billion |
|
Mayne Pharma Group Ltd
AU:MYX
|
Australia | AU$1.01 Billion |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
|
China | CN¥235.37 Billion |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332
|
China | CN¥89.76 Billion |
|
Jointown Pharmaceutical Group Co Ltd
SHG:600998
|
China | CN¥112.28 Billion |
Cyclopharm Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.53 | 3.99 | 2.81 |
| Quick Ratio | 1.51 | 2.75 | 1.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$17.20 Million | AU$31.77 Million | AU$10.29 Million |
Cyclopharm Ltd - Advanced Valuation Insights
This section examines the relationship between Cyclopharm Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.81 |
| Latest Market Cap to Assets Ratio | 1.09 |
| Asset Growth Rate (YoY) | -25.8% |
| Total Assets | AU$46.10 Million |
| Market Capitalization | $50.40 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cyclopharm Ltd's assets above their book value (1.09x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Cyclopharm Ltd's assets decreased by 25.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cyclopharm Ltd (2005–2025)
The table below shows the annual total assets of Cyclopharm Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | AU$46.10 Million ≈ $32.62 Million |
-25.80% |
| 2024-12-31 | AU$62.13 Million ≈ $43.96 Million |
+35.31% |
| 2023-12-31 | AU$45.91 Million ≈ $32.49 Million |
-7.32% |
| 2022-12-31 | AU$49.54 Million ≈ $35.05 Million |
-11.12% |
| 2021-12-31 | AU$55.74 Million ≈ $39.44 Million |
+97.14% |
| 2020-12-31 | AU$28.28 Million ≈ $20.01 Million |
-13.08% |
| 2019-12-31 | AU$32.53 Million ≈ $23.02 Million |
+38.20% |
| 2018-12-31 | AU$23.54 Million ≈ $16.65 Million |
+0.68% |
| 2017-12-31 | AU$23.38 Million ≈ $16.54 Million |
+42.41% |
| 2016-12-31 | AU$16.41 Million ≈ $11.61 Million |
-0.76% |
| 2015-12-31 | AU$16.54 Million ≈ $11.70 Million |
+50.90% |
| 2014-12-31 | AU$10.96 Million ≈ $7.76 Million |
+21.65% |
| 2013-12-31 | AU$9.01 Million ≈ $6.38 Million |
-58.39% |
| 2012-12-31 | AU$21.66 Million ≈ $15.32 Million |
+1.71% |
| 2011-12-31 | AU$21.29 Million ≈ $15.07 Million |
-3.83% |
| 2010-12-31 | AU$22.14 Million ≈ $15.67 Million |
+12.71% |
| 2009-12-31 | AU$19.64 Million ≈ $13.90 Million |
+5.73% |
| 2008-12-31 | AU$18.58 Million ≈ $13.15 Million |
+69.25% |
| 2007-12-31 | AU$10.98 Million ≈ $7.77 Million |
+21.15% |
| 2006-12-31 | AU$9.06 Million ≈ $6.41 Million |
-56.84% |
| 2005-12-31 | AU$20.99 Million ≈ $14.86 Million |
-- |
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more